A Six-Month Supplementation of Mulberry, Korean Red Ginseng, and Banaba Decreases Biomarkers of Systemic Low-Grade Inflammation in Subjects with Impaired Glucose Tolerance and Type 2 Diabetes by Kim, H.-J. et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 735191, 8 pages
doi:10.1155/2012/735191
Research Article
A Six-Month Supplementation of Mulberry,
KoreanRedGinseng,andBanaba DecreasesBiomarkersof
SystemicLow-Grade Inﬂammation in Subjectswith Impaired
GlucoseTolerance and Type 2 Diabetes
H.-J. Kim,1 K.-H. Yoon,2 M.-J. Kang,2 H.-W.Yim,3 K.-S. Lee,4 V. Vuksan,5 andM.-K. Sung1
1Department of Food and Nutrition, Sookmyung Women’s University, Yongsan-gu, Seoul 140-742, Republic of Korea
2Department of Endocrinology and Metabolism, Seoul St. Mary’s Hospital The Catholic University of Korea, Seocho-gu,
Seoul 137-701, Republic of Korea
3Department of Preventive Medicine, Seoul St. Mary’s Hospital The Catholic University of Korea, Seocho-gu,
Seoul 137-701, Republic of Korea
4Korea Ginseng Manufacturing Plant, National Agricultural Cooperative Federation, Chung-buk 368-811, Republic of Korea
5Clinical Nutrition & Risk Factor Modiﬁcation Center, St. Michael’s Hospital and, Department of Nutritional Sciences,
University of Toronto, Toronto, ON, Canada M5C 1N8
Correspondence should be addressed to M.-K. Sung, mksung@sm.ac.kr
Received 5 October 2011; Revised 19 December 2011; Accepted 20 December 2011
Academic Editor: Cheorl-Ho Kim
Copyright © 2012 H.-J. Kim et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We sought the long-term eﬃcacy of traditionally used antidiabetic herbs in controlling blood glucose homeostasis and low-grade
inﬂammation. Ninety-four subjects with either impaired glucose tolerance or mild T2D were randomized either to treatment arm
or placebo arm and received 1:1:1 mixture of ginseng roots, mulberry leaf water extract, and banaba leaf water extract (6g/d)
for 24 weeks. Oral 75g glucose tolerance test was performed to measure glucose and insulin responses. Blood biomarkers of low-
gradeinﬂammationwerealsodetermined.Resultsfoundnosigniﬁcantdiﬀerenceinglucosehomeostasiscontrolmeasurechanges.
However, plasma intracellular adhesion molecule-1 (ICAM-1) concentration was decreased showing a signiﬁcant between-
treatment changes (P = 0.037). The concentrations of vascular cell adhesion molecule-1 (VCAM-1) (P = 0.014) and ICAM-1
(P = 0.048) were decreased in the treatment group at week 24, and the oxidized low-density lipoprotein (ox-LDL) concentration
was reduced at week 24 compared to the baseline value in the treatment group (P = 0.003). These results indicate a long-term
supplementation of ginseng, mulberry leaf, and banaba leaf suppresses inﬂammatory responses in T2D.
1.Introduction
Type 2 diabetes (T2D) is the fastest growing metabolic dis-
order in many parts of the world. The incidence of T2D in
2000 is ∼171 million worldwide, and this number is esti-
mated to be doubled in 2030 [1]. T2D has higher risk of
developing vascular complications which increase the risk
of cardiovascular diseases (CVDs). Recent studies have also
suggested that impaired glucose tolerance is a risk factor
for CVD independent of the subsequent T2D development
[2, 3]. Therefore, the reversal of impaired glucose tolerance
(IGT) to normal glucose tolerance (NGT) is an important
strategy to prevent both T2D and CVD.
The frequent development of type 2 diabetes and CVD
among obese population is possibly related to excess adipos-
ity and subsequent low-grade chronic inﬂammation [4, 5].
Theelevatedconcentrationsofcirculatingfreefattyacidsand
inﬂammatory mediators in obese subjects create insulin re-
sistance [6, 7] which is associated with a cluster of metabolic
abnormalities including dyslipidemia, hyperglycemia, and
hypertension [8] followed by the development of premature
atherosclerosis as well as type 2 diabetes. The postprandial2 Evidence-Based Complementary and Alternative Medicine
glucose excursion has been suggested as an independent
factor to activate thrombotic conditions through a transient
overproduction of reactive oxygen species [9].
A growing number of people with T2D use alternative
therapies including herbal medicines, and many of them are
not proven for their eﬃcacies. Ginseng has been used for
many years as one of the most popular folk herbal remedies
to manage symptoms of diabetes. However, it is not until
recent years to provide scientiﬁc evidence that ginseng pos-
sesses blood glucose control activities possibly by enhancing
insulin sensitivity [10]. We have previously reported that
Korean red ginseng root, mixed with mulberry leaves and
banaba leaves, exerts eﬃcient regulation of blood glucose
homeostasis in db/db mouse [11]. Mechanistic explanations
included the upregulation of liver PPAR-α, adipose tissue
PPAR-γ, and lipoprotein lipase (LPL) gene expression, which
improved insulin sensitivity and lipid metabolism. Mulberry
leave extract has been shown to possess hypoglycemic eﬀects
in an IDDM animal model, and a potential hypoglycemic
compound in mulberry leaves was suggested as 2-O-α-
D-galactopyranosyl-DNJ) and fagomine [12]. Banaba leaf
extract has been shown to regulate blood glucose concen-
tration, and active compounds are identiﬁed as corosolic
acid and penta-O-galloyl-glucopyranose [13] which improve
lipid metabolism or glucose uptake, respectively. Therefore
the hypothesis of this study was the supplementation of red
ginseng roots, mulberry leaf water extract, and banaba leaf
water extract for 6 months improves blood glucose home-
ostasis by increasing insulin sensitivity and suppresses low-
grade inﬂammation in subjects with impaired glucose toler-
ance or mild cases of T2D.
2.MaterialsandMethods
2.1. Study Population. Individuals with impaired glucose
tolerance and mild cases of T2D were recruited based on the
report of the Expert Committee on the Diagnosis and Classi-
ﬁcation of Diabetes Mellitus [14] Eligibility criteria included
35–79 years old, BMI over 20kg/m2, and nonpregnant who
has not taken herbs at least for the last 3 months. Exclusion
criteria were patients taking insulin or medications other
thansulfonylurea,biguanide,orα-glucosidaseduringthelast
2 months individuals with chronic liver diseases, advanced
kidney diseases, atherosclerosis, myocardial infarction, pul-
monarydiseases,gastrointestinaldiseases,hematologicaldis-
eases, and cancer. Individuals receiving or have received
pharmacological doses of steroids and/or participating in
weight reduction programs were also excluded. The sample
size was calculated based on a previous clinical trial [10], and
80min·mmol/L reduction in the total area under the curve
of glucose during the oral glucose tolerance test (OGTT
AUCg) was considered to be the primary eﬃcacy point with
the average standard deviation (SD) of 105min·mmol/L at
a two-tailed alpha = 0.05 and 1-β = 90%. The study was
approved by the Seoul St. Mary’s Hospital ethics review
board, and eligible participants gave informed written
consent.
2.2. Study Design. The study used a randomized, placebo-
controlled, double-blind, parallel design. The enrolled
subjectsbeganontheplaceborun-inperiodfor4weekstobe
acclimatized to the treatment protocol and stabilize baseline
measures (Figure 1). The treatment protocol was determined
from the previous Korean red ginseng clinical trial [10]. The
total treatment dose was 6g/day (2g× 3 times taken 40min
before each meal). Placebo capsules were prepared with
cornstarch.Treatmentswereconcomitantwithusualtherapy,
and dietary counseling was provided based on the guideline
of the Korean Society of Diabetes/Korean Association of
Dietetics. The treatment period was 6 months, and each
enrolled participant visited the hospital every 3 months to
have clinical and biochemical measurement taken, receive
next treatment capsules, and return unused capsules. Three-
day dietary records were collected during the last three days
before visit 1 (baseline) and visit 3 (week 24). Demographics
measures, anthropometric measures, and exercise habits
were obtained from study participants at all visits. The type
and dose of oral medication were maintained throughout
the study. Compliance measures included the number of
returned capsules, body weight, and 3-day dietary records
which was reviewed by a trained dietitian using food and
portion size models.
2.3. Preparation of Supplements. The Korean red ginseng
(Panax ginseng C.A. Mayer) powder, mulberry (Morus alba
L.)leafwaterextractpowder,andbanaba(Lagerstroemiaspe-
ciosa L.) leaf water extract powder were kind gifts from
the National Agricultural Cooperative Federation (Jeung-
p y e o n g ,R e p u b l i co fK o r e a ) .T h r e eh e r b a lp r e p a r a t i o n sw e r e
mixed in equivalent ratio and encapsulated (500mg/cap-
sule). The preparation procedures for each herb are de-
scribed in the previous report [11]. Quality control of the
herb mixture was based on the contents of the marker sub-
stances which are total ginsenosides for red ginseng pow-
der, corosolic acid for banaba leaf extract, and 1-deoxynojir-
imycin for mulberry leaf extract.
2.4. Outcome Measures. Overnight fasting venous blood
samples were collected at each visit to measure biochemical
eﬃcacyindices.PlasmaHbA1c,glucose,andinsulinwerean-
alyzed at the central laboratory of Seoul St. Mary’s Hospital.
The 75g oral glucose tolerance test with venous blood
collected at 0, 30, and 120min was also performed. The
homeostasis model assessment insulin (HOMA-IR) and
the insulin sensitivity index estimated from oral glucose
tolerance test (ISIOGTT) were calculated. Homeostasis model
assessment of insulin resistance was calculated according
to the formula: fasting insulin (μU/mL) × fasting glucose
(mmol/L)/22.5 [15]. Low-grade systemic inﬂammatory
markers measured included intracellular adhesion molecule-
1(ICAM-1), vascular cell adhesion molecule-1(VCAM-1),
oxidized low-density lipoprotein (ox-LDL), plasminogen
activator inhibitor-1(PAI-1), lipoprotein(Lp)(a), and high-
sensitivity C-reactive protein(hs-CRP). Blood lipid proﬁles
were also determined. The enzyme-linked immunosorbent
assay (ELISA) was used to determine plasma ICAM-1 (R&D,
MN, USA), VCAM-1 (R&D, MN, USA), ox-LDL (Merco-
dia AB, Stockholm, Sweden), LP(a) (Progen, Heidelberg,
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Figure 1: Schematic of the ﬂow of study participants. A total of 118 individuals agreed to participate were screened, and 94 subjects began
on the placebo run-in period for 4 weeks to be acclimatized to the treatment protocol and stabilize baseline measures. The study subjects
were randomly allocated to either placebo group or supplement group. Final analyses included 30 subjects in placebo group and 32 subjects
in supplement group.
Fullerton, CA USA). The intra- and interassay variability for
inﬂammatory markers were 4.6 and 5.5% for ICAM-1, 3.1
and 7.0% for VCAM-1, 6.3 and 4.7% for ox-LDL, 5.0 and
8.0% for LP(a), 6.7 and 7.3% for PAI-1, and 3.8 and 4.8%
for hs-CRP. Adverse eﬀects were monitored at each visit,
and serum creatinine concentration, the activity of aspartate
amino transferase (AST) and alanine amino transferase
(ALT) were measured as safety biochemical measures.
2.5. Statistical Analyses. Per-protocol analyses were con-
ducted.Dailynutrientintakewascalculatedasthemeandaily
intake from 3-day dietary record using the Computer-Aided
Nutritional Analysis Program version 3 (Korea Nutrition
Society, Seoul, Korea). Statistical analyses were conducted
using the SAS program version 9.1 (SAS Institute Inc., Cary,
NC, USA). Descriptive data was expressed as means ± SD.
For comparison of data between the two groups, we used
the unpaired t-test for data with normal distribution and the
Wilcoxon Rank Sum test for data with skewed distribution.
3. Result
One hundred eighteen individuals were assessed for their
eligibility, and 94 individuals met the inclusion criteria.
Among these participants, 32 dropped out of the study due
to shortfalls in required (80%) capsule intake, changes in
medication, refusal to continue, and a case of adverse event.
One person on treatment dropped out of the study due to
mild symptoms of muscle aching, nausea, and dry lips. The
demographic and physical characteristics of study partici-
pants are shown in Table 1, and no signiﬁcant diﬀerence
was found due to herbal supplementation. Smoking habits,
alcohol consumption, and physical activity of treatment
and placebo groups were not diﬀerent at baseline. No
signiﬁcant change was observed with daily nutrient intake
from baseline to 6 months (Table 2). Body weight, BMI,
waist circumference, and blood pressure measures were not
signiﬁcantly changed from baseline to 6 months (Table 2).
3.1. Blood Glucose Homeostasis Indices. Within- and be-
tween-treatment diﬀerences were assessed for herb prepara-
tion and placebo in fasting and 75g OGTT indices of glucose
and insulin (Table 3). Fasting blood glucose and insulin
concentrations did not show signiﬁcant diﬀerences either
within- or between-treatment group. There were signiﬁcant
within-treatment changes in 75g OGTT AUCg for both
groups while no signiﬁcance was found in between-treat-
ment changes. There was a trend of decreased total area
under the curve of insulin during the 75g oral glucose toler-
ance test (75g OGTT AUC) in treatment group; however no
statistical signiﬁcance was observed. Neither the within- nor
the between-treatment diﬀerences in HbA1C was signiﬁcant.4 Evidence-Based Complementary and Alternative Medicine
Table 1: Basic characteristics of study subjects.
Herb group (n = 32) (%) Placebo group (n = 30) (%)
Age (year) 58.9 ±8.9(1) 56.6 ±9.6
Sex (Man %) 32 (68.75)
(2) 30 (73.33)
Height (cm) 164.3 ±7.9 165.8 ±7.9
Weight (kg) 68.5 ±12.16 9 .9 ±9.8
BMI (kg/m2)(3) 25.3 ±3.42 5 .4 ±2.5
Waist (cm) 89.1 ±6.89 1 .2 ±6.3
Blood pressure (mHg)
Systolic 118.9 ±15.1 129.7 ±13.5
Diastolic 80.2 ±10.48 2 .8 ±7.0
Smoking status
Yes 8 (25) 6 (20)
No 24 (75) 24 (80)
Alcohol consumption
Yes 17 (53.12) 20 (66.67)
No 15 (46.88) 10 (33.33)
Frequency of exercise
None 4 (12.50) 5 (16.66)
1-2/week 5 (15.63) 8 (26.66)
3-4/week 10 (31.25) 5 (16.67)
5-6/week 7 (21.88) 1 (3.33)
Almost everyday 6 (18.75) 11 (36.67)
(1)Mean ±SD.
(2)Number of subjects (%).
(3)Body mass index.
Table 2: Follow-up changes in anthropometry and nutrient intake.
Herb group (n = 32) Placebo group (n = 30)
Weight (kg) Baseline 68.5 ±12.1(1) 69.9 ±9.8
Week 24 67.6 ±12.76 8 .3 ±9.4
BMI (kg/m2)(2) Baseline 25.3 ±3.42 5 .4 ±2.5
Week 24 24.9 ±3.62 4 .8 ±2.4
Waist (cm) Baseline 89.1 ±6.89 1 .2 ±6.3
Week 24 87.8 ±7.38 8 .8 ±6.9
Blood pressure (mmHg)
Baseline (sys.) 118.9 ±15.1 129.7 ±13.5
Week 24 (sys.) 113.1 ±12.0 119.2 ±13.4
Baseline (dia.) 80.2 ±10.48 2 .8 ±7.0
Week 24 (dia.) 75.9 ±8.77 5 .8 ±8.1
Energy (kcal) Baseline 1710.1 ±375.6 1657.9 ±396.1
Week 24 1700.5 ±336.3 1734.5 ±427.6
Animal protein (g) Baseline 34.8 ±18.03 3 .7 ±18.9
Week 24 36.9 ±23.33 9 .2 ±26.3
Plant protein (g) Baseline 37.7 ±10.93 4 .8 ±8.7
Week 24 38.5 ±11.73 4 .5 ±9.6
Carbohydrate (g) Baseline 257.2 ±60.6 232.5 ±54.0
Week 24 245.5 ±49.5 242.8 ±58.8
Animal fat (g) Baseline 21.4 ±15.82 3 .4 ±19.0
Week 24 26.5 ±22.82 5 .8 ±19.5
Plant fat (g) Baseline 20.3 ±11.91 7 .7 ±9.2
Week 24 20.2 ±11.21 9 .1 ±9.5
(1)Mean ± SD.
(2)Body mass index.Evidence-Based Complementary and Alternative Medicine 5
Table 3: Between treatment diﬀerences in blood glucose homeostasis indices following 6-month supplementation with herbal preparation
or placebo in subjects with IGT or mild T2D.
Treatment (n = 32) Placebo (n = 30)
Baseline 12 week 24 week Baseline 12 week 24 week
Fasting glucose1 6.93 ±1.15 7.04 ±1.19 6.79 ±1.37 7.54 ±1.47 7.4 ±1.49 7.04 ±1.08
Fasting insulin2 9.65 ±5.45 11.03 ±8.70 9.67 ±4.57 8.93 ±4.98 9.43 ±5.05 9.32 ±6.15
HOMA-IR 2.99 ±1.89 3.61 ±3.44 2.92 ±1.54 3.02 ±1.72 3.15 ±1.80 2.83 ±1.73
OGTT AUC
3
g 23.83 ±5.51 23.26 ±5.15 21.87 ±5.08† 25.27 ±6.12 24.64 ±4.79 23.27 ±4.65†
OGTT AUC
4
i 93.79 ±62.77 88.67 ±55.55 81.55 ±44.32 81.1 ±50.71 74.75 ±53.28 88.79 ±76.88
ISIOGTT 5.97 ±6.13 5.72 ±4.69 5.57 ±3.66 5.51 ±4.68 5.69 ±4.40 6.44 ±6.34
HbA1c (%) 6.37 ±0.60 6.39 ±0.71 6.45 ±0.67 6.52 ±0.74 6.52 ±0.86 6.54 ±0.70
Mean diﬀerence (treatment versus placebo)
0–12 12–24 0–24
Fasting glucose1 −0.24 ±1.56 −0.11 ±1.52 −0.35 ±1.54
Fasting insulin2 −0.89 ±8.86 1.26 ±10.45 0.37 ±7.08
HOMA-IR −0.49 ±3.21 0.37 ±3.59 −0.12 ±2.07
OGTT AUC
3
g −0.06 ±6.52 0.03 ±5.50 −0.03 ±5.71
OGTT AUC
4
i −1.24 ±56.74 21.16 ±53.85 19.92 ±66.28
ISIOGTT 0.43 ±6.85 0.89 ±6.12 1.32 ±8.58
HbA1c (%) −0.03 ±0.68 −0.03 ±0.81 −0.06 ±0.76
1uM/mL, 2μU/mL, 3uM/mL, 4μU/mL.
†signiﬁcantly diﬀerent within-treatment change from baseline (P<0.05, paired t-test).
3.2. Blood Inﬂammatory Indices Related to Vascular Compli-
cations. Within- and between-treatment diﬀerences were as-
sessed for herb preparation and placebo in inﬂammatory
indices (Table 4). The plasma ICAM-1 concentration was
decreased by 4.7% in treatment group and increased by
8.2% in placebo group at week 24 compared to the baseline
value showing a signiﬁcant between-treatment changes (P =
0.037). The plasma VCAM-1 and ox-LDL concentrations
were decreased by 7.9% and 13.6% in treatment group at the
end of study compared to those at the baseline (P = 0.040
and P = 0.003, resp.). There were signiﬁcant diﬀerences in
VCAM-1 and ICAM-1 concentration change between week
1 2a n dw e e k2 4( P = 0.014 and P = 0.048, respectively). Ox-
LDL concentration was decreased at wk 24 compared to the
baseline value in the treatment group (P = 0.003); however,
no signiﬁcant between group diﬀerence was found.
3.3. Safety Measures. There was one case of drop-out due
to mild adverse eﬀects including gastrointestinal discomfort,
rashes, muscle ache, and dry lips. No signiﬁcant diﬀerence
was found for biochemical safety indices (data not shown).
4. Discussion
The present study is one of few well-controlled long-term
human intervention trials to evaluate the eﬃcacy of tra-
ditional herbs with a long historical use for diabetes. We
have previously shown that the oral supplementation of
these herbs eﬀectively delays the development of insulin re-
sistance and subsequent hyperglycemia in db/db mice [11].
Six months of supplementation with mulberry extract, Kore-
an red ginseng root, and banaba extract (6g/d) decreases
biomarkers of systemic low-grade inﬂammation in subjects
with impaired glucose tolerance or mild cases of type 2
diabetes. However, there was no signiﬁcant improvement in
blood glucose homeostasis biomarkers. Safety measures in-
cluding hepatic, renal and hemostatic functions and blood
pressure did not diﬀer between the herb and placebo group.
Excess body fat leads to insulin resistance and low grade
chronic inﬂammatory status posing high risk of developing
CVD as well as type 2 diabetes. Therefore, improvement
in insulin resistance has been suggested as eﬀective mean
to delay or prevent the progress of life-style-related T2D
and vascular complications. We studied the eﬃcacy of the
selectedherbalpreparationinsubjectswithimpairedglucose
tolerance or mild T2D because these herbs have been shown
to improve insulin sensitivity and lipid metabolism which
are characteristic early-phase metabolic disturbances during
the development of T2D. Study results indicated that the
supplementation of herbal preparations improved markers
of inﬂammation which is related to the vascular thrombosis.
There was a signiﬁcant treatment diﬀerence in circulating
concentrations of ICAM-1. The within-group improvements
in VCAM-1 and ox-LDL concentrations were also found.
Insulin resistance was associated with subclinical inﬂam-
mationinthepopulationwhowereatriskofdevelopingT2D
[16, 17]. Low-grade inﬂammation is a well-established risk
factor of atherosclerosis [18], and this was used to explain
microvascular complications frequently occurring in T2D.
The oral lipid overload increased CRP and HOMA-IR in
IGT subjects [19] suggesting there is an increase in the risk
of vascular thrombosis before the diagnosis of diabetes. Evi-
dences indicates that clinical cardiovascular disease can also
precede development of T2D [20]. Plasma concentrations of6 Evidence-Based Complementary and Alternative Medicine
Table 4: Between treatment diﬀerences in inﬂammation indices following 6-month supplementation with herbal preparation or placebo in
subjects with IGT or mild T2D.
Treatment (n = 32) Placebo (n = 30)
Baseline 12 week 24 week Baseline 12 week 24 week
ICAM (ng/mL) 224.4 ±76.82 197.0 ±67.5∗¶ 213.8 ±85.19 218. 7 ±102.6 199.0 ±85.10† 236.7 ±109.6
VCAM (ng/mL) 668.4 ±171.5 651.8 ±174.3 615.3 ±201.8† 701.2 ±223.9 660.9 ±228.0 707.9 ±315.1
ox-LDL (U/I) 60.2 ±17.55 63.82 ±18.28 51.98 ±13.99‡ 60.82 ±20.49 60.77 ±20.81 54.68 ±13.62
Lp(a) (mg/dL) 25.34 ±16.25 22.91 ±17.80 26.98 ±19.77 26.96 ±19.41 24.01 ±19.04† 25.65 ±19.95
PAI-1 (ng/mL) 5.65 ±3.33 6.61 ±4.69 5.59 ±3.84 7.55 ±12.36 6.21 ±4.56 6.37 ±5.27
Hs-CRP (ng/mL) 1.64 ±1.90 1.66 ±1.18 1.33 ±1.42 2.05 ±2.94 1.55 ±1.74 1.87 ±2.96
Mean diﬀerence (treatment versus placebo)
0–12 12–24 0–24
ICAM (ng/mL) 7.73 ±57.54 20.89 ±59.7a 28.62 ±72.94
b
VCAM (ng/mL) −23.6 ±184.1 83.39 ±199.2a 59.76 ±244.9
ox-LDL (U/I) −3.67 ±21.78 5.74 ±18.71 2.07 ±17.65
Lp(a) (mg/dL) −0.52 ±10.19 −2.43 ±13.34 −2.95 ±12.87
PAI-1 (ng/mL) −2.3 ±13.00 1.18 ±5.65 −1.12 ±13.13
Hs-CRP (ng/mL) −0.52 ±3.97 0.65 ±2.54 0.13 ±4.25
∗signiﬁcantly diﬀerent within-treatment change from baseline (P<0.05, paired t-test) † < 0.05 ‡ < 0.01 ¶ < 0.001.
asigniﬁcantly diﬀerent between-treatment change during week 12–24 (P<0.05, the Wilcoxon rank sum test).
bsigniﬁcantly diﬀerent between-treatment change during week 0–24 (P<0.05, the Wilcoxon rank sum test).
E-selectin, ICAM-1, and VCAM-1 as markers of endothelial
dysfunction were proven to predict development of T2D in
initially nondiabetic women [21], and the association was
independent of other known risk factors such as subclinical
inﬂammation and obesity. Our study results also suggested
that the circulating concentration of ox-LDL is improved in
the treatment group. The increased oxidative stress increases
the oxidized products including ox-LDL which is often
elevated in T2D [22]. The overproduction of reactive oxygen
species in the adipose tissue and liver of the experimental
animals preceded the onset of obesity and insulin resistance
[23]. ox-LDL is shown to impair adipocyte response to
insulin and degrade insulin receptor substrate-1 (IRS-1)
[24]. Ox-LDL is also reported to enhance atherogenecity and
reduce HDL-cholesterol metabolism in T2D by suppressing
lecithin-cholesterol acyltransferase activity [25].
We have previously shown that mulberry extract, Korean
red ginseng, and banaba extract act as PPAR-α and PPAR-γ
agonists improving lipid metabolism in leptin-deﬁcient db/
db mice [11]. PPARs are ligand-activated transcription fac-
tors belonging to the nuclear receptor superfamily. PPAR-α
agonists stimulate the cellular uptake of free fatty acids,
the cellular lipid storage, and the transportation of free
fatty acids by regulating the expression of genes involved
in lipid metabolism [26]. A previous study showed that
PPAR-γ agonists suppressed TNF-α-induced ICAM-1 ex-
pressioninendothelialcells[27]andvascularsmoothmuscle
cells [28] indicating these herbs possibly reduced ICAM and
VCAM concentrations possibly by acting as PPARs agonists.
Polyphenols present in these herbs may have exerted antiox-
idant activities possibly contributing to the reduced level
of ox-LDL which decreases the risk of developing insulin
resistance.
In this study, little improvement was observed in blood
glucose homeostasis markers upon 6 months of supplemen-
tation with herbal preparation (6g/d). The proportion of
subjects with IGT and diabetes in this study were 56%:44%
in the treatment group and 57%:43% in the placebo group,
respectively. No signiﬁcant improvement in the treatment
group was found in glucose homeostasis biomarkers in the
subset analyses where IGT subjects and T2D subjects were
separately analyzed for the diﬀerence between the treatment
and the placebo (data not shown). The large standard
deviations in glucose homeostasis blood markers may be
derived from the heterogeneity of study subjects. The IGT
subjects were selected based on their fasting plasma glucose,
and a previous report has suggested that fasting plasma glu-
cose may not be the best predictor of insulin sensitivity
[29] which is an event of metabolic dysfunction possibly
regulated by the selected herbal preparation. Therefore, as
indicated in study results, the fasting insulin concentration
showed large variations at baseline. Low- or high-GI diet in
also failed to regulate blood lipids or fasting insulin in IGT
subjects [30] suggesting the eﬃcacy evaluation of insulin-
sensitizing compounds or herbal preparations may require
study subjects exhibiting abnormalities more in insulin-
associated metabolic features.
In a previous clinical study to evaluate the eﬃcacy of Ko-
rean red ginseng root preparation in type 2 diabetes patients,
6g/d of Korean red ginseng improved OGTT-PI after 12
weeks of supplementation without concomitant improve-
ment in glucose control [10]. This study used a combination
ofthreediﬀerentherbswhichmayhavelessabilitytoregulate
insulin resistance compared to red ginseng itself in this study
subjects. We have reported that the combination of these
three herbs suppresses the development of insulin resistance
in leptin-deﬁcient db/db mouse which is an animal model of
obesity-inducedT2D[11].Themodeofhypoglycemicaction
is explained as the upregulation of liver PPAR-α, adipose tis-
sue PPAR-γ, and lipoprotein lipase (LPL) gene expression
which possibly improved lipid metabolism. The average
body mass indices of our study subjects were 25.3 and 25.4Evidence-Based Complementary and Alternative Medicine 7
for the treatment and placebo group, and therefore, the
metabolicdysregulationmayhavenotbeenextensiveenough
to respond to the test material. In fact subjects participating
in the study maintained circulating glucose and insulin
concentrations that are close to normal range.
Another possible explanation for the absence of glucose
control eﬃcacy is the herb-herb interaction. Although we
found no report on interactions between herbs used in this
study, it has been reported that multiple interaction mech-
anisms exist between ingested herbs and drugs aﬀecting
their indented beneﬁcial eﬀects. A recent review indicated
that the active constituents may compete for absorption and
transportation by using same transport proteins, and herbal
components can change the gastrointestinal motility and/or
pH. In many cases, drug-metabolizing enzymes are targets
of competition for herbal constituents and medical drugs
[31].
It is important to be aware of possible drug-herb inter-
actions because it will eventually aﬀect eﬃcacy and toxicity
of drugs. Ginseng is known to alter anticoagulant eﬀect of
warfarin [32]. It is also reported that the concomitant use
of monoamine oxidase inhibitor phenelzine and ginseng
mayresultininsomnia,headache,tremulousness,andmania
[33]. Morin, the active constituent in mulberry is shown to
interact with cyclosporine, an immunosuppressant [34]. Ba-
naba extract has been shown to increase the bioavailability of
dopamine by inhibiting cytosolic sulfotrasferase [35].
There are several limitations in this study. We observed
the placebo eﬀect in insulin response markers, and this may
contribute to null conclusions. Although we conﬁrmed there
was no diﬀerence in the average weight or dietary intake dur-
ing the study period for both treatment and placebo arms,
participants may have maintained very healthy life-styles
during the study. Also, it is now well accepted that there
are large individual variations in the metabolism of active
compounds in herbs which may have caused large intraindi-
vidualvariationstoexertbiologicalactivities.Arecentreview
indicated that agricultural pollutants such as organophos-
phates and organochlorines aﬀect cellular metabolism of
carbohydrate and lipid thereby developing insulin resistance
and impaired glucose homeostasis [36]. Alterations of en-
zyme activities and the increased oxidative stress have been
suggested as possible mechanisms of action. Although the
test herbs used in this study met the food-grade quali-
ty, appropriate studies to elucidate possible interactions be-
tween pollutants and glucose/lipid metabolism are needed.
Due to a long supplementation period, we adopted a parallel
design instead of the cross-over design which may have
created large interindividual variations. Finally this study
does not provide mechanistic explanations or information
on active compounds, which need further investigation.
5. Conclusion
A long-term supplementation of mulberry, Korean red gin-
seng, and banaba leaf improved low-grade systemic inﬂam-
mation without signiﬁcant eﬃcacy in blood glucose home-
ostasis control. The fast growing incidence of T2D requires
early detection and prevention. The complementary use of
dietary supplement may be used to delay the disease pro-
gression at early stage. The chemical complexity of herbal
products and large interindividual responses needs to be
considered carefully in future clinical trials.
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